Medifast, Inc. (MED) Q2 2025 Earnings Call Transcript

Medifast reported Q2 2025 revenue of $105.6 million, a 37.4% year-over-year decrease, though it achieved net income of $2.5 million ($0.22 EPS) compared to a prior-year loss, primarily due to reduced SG&A and a gain from liquidating LifeMD stock. Active coaches declined 32.7% to 22,800, and average revenue per coach fell, partly reflecting the absence of promotions this quarter. Strategically, Medifast is repositioning its programs to complement GLP-1 usage by emphasizing lean mass preservation and long-term metabolic health, while implementing new initiatives like Premier+ pricing and the EDGE program to enhance coach productivity and recruitment. The company forecasts Q3 revenue of $70 million to $90 million and EPS of $0.00 to a loss of $0.60, underscoring its ongoing business transformation efforts.

Analysis

Medifast (MED) reported Q2 2025 results that reflect a company in a deep, ongoing transformation. Revenue declined sharply by 37.4% year-over-year to $105.6 million, primarily driven by a 32.7% decrease in active coaches to 22,800 and a 6.9% fall in average revenue per coach. Despite this top-line pressure, the company engineered a swing to a net income of $2.5 million, or $0.22 per share, from a significant loss in the prior-year period. This profitability was not a result of core operational strength but was achieved through a 40.8% reduction in SG&A expenses, aided by non-recurring costs in the 2024 comparison period, and a $2.6 million gain from the complete liquidation of its LifeMD common stock. Strategically, management is repositioning the business to coexist with the rise of GLP-1 medications by emphasizing its program's ability to preserve lean muscle mass and instill long-term metabolic health habits—addressing key weaknesses of GLP-1-only treatments. New initiatives, such as the simplified 'Premier+' pricing model and the 'EDGE' coach incentive program, are being implemented to stabilize the business. However, the forward outlook remains challenging, with Q3 revenue guided to a range of $70 million to $90 million and EPS from breakeven to a loss of $0.60, signaling that near-term financial headwinds will persist.

Key Decisions for Investors

• Investors should exercise caution, as the severe revenue and coach count declines, coupled with a weak Q3 forecast for further contraction and potential losses, indicate that the business turnaround is in its early stages with significant execution risk.
• Monitor key performance indicators beyond headline revenue, specifically looking for stabilization in the active coach count and sequential growth in revenue per coach as potential early signs that new initiatives like Premier+ and EDGE are gaining traction.
• While the strong balance sheet with $162.7 million in cash and no debt provides a crucial buffer, the guided shift to a potential net loss in Q3 highlights the need to watch for cash burn, as sustained negative operating performance could erode this key strategic advantage.